Last $2.03 USD
Change Today +0.1099 / 5.72%
Volume 195.2K
OXGN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 11:12 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

oxigene inc (OXGN) Snapshot

Open
$1.94
Previous Close
$1.92
Day High
$2.03
Day Low
$1.93
52 Week High
03/12/14 - $5.40
52 Week Low
10/15/14 - $1.75
Market Cap
42.0M
Average Volume 10 Days
744.6K
EPS TTM
$-2.90
Shares Outstanding
20.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OXIGENE INC (OXGN)

oxigene inc (OXGN) Related Bloomberg News

View More Bloomberg News

oxigene inc (OXGN) Related Businessweek News

No Related Businessweek News Found

oxigene inc (OXGN) Details

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops therapeutics primarily to treat cancer. The company focuses on developing vascular disrupting agents (VDAs) that disrupt abnormal blood vessels associated with solid tumor progression. Its principal clinical product candidate is ZYBRESTAT, which is in development as a treatment for solid tumors. The company is also developing OXi4503, a second-generation product candidate for acute myeloid leukemia. OXiGENE, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

9 Employees
Last Reported Date: 03/20/14
Founded in 1988

oxigene inc (OXGN) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $241.3K
Compensation as of Fiscal Year 2013.

oxigene inc (OXGN) Key Developments

OXiGENE, Inc. Initiates Phase 2 Study of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors

OXiGENE, Inc. announced that the first patient has been enrolled in a Phase 2 study to evaluate the safety and activity of fosbretabulin monotherapy in patients with locally advanced, recurrent or metastatic gastrointestinal neuroendocrine tumors, or GI-NETs, with elevated biomarkers. GI-NETs are slow-growing, often invasive tumors that produce excessive amounts of hormones and other peptides which enter the blood stream and cause debilitating symptoms. The Phase 2 study will evaluate the safety and activity of fosbretabulin monotherapy in approximately 20 GI-NET patients with increased biomarkers and/or clinical symptoms. The study will evaluate the impact of fosbretabulin on certain biological mediators over time, following the patient's baseline measurements at the study start. The primary endpoint of the trial is the reduction of biomarkers, and secondary endpoints include improvement in symptoms and quality of life as assessed by validated measures. The study will be conducted at five sites in the U.S.

OXiGENE, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014

OXiGENE, Inc. Presents at 13th Annual BIO Investor Forum, Oct-07-2014 . Venue: The Palace Hotel, San Francisco, CA 94105, United States.

OXiGENE, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

OXiGENE, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported a net loss of $3.924 million compared to a net loss of $1.655 million for the comparable three-month period in 2013. The increase in the net loss in 2014 as compared to 2013 was primarily due to an increase in research and development (R&D) expenses of approximately $1.6 million in the second quarter of 2014 as compared to the prior year period. Loss from operations was $3,924,000 compared to $1,655,000 a year ago. Net loss attributable to common stock was $3,929,000 compared to $4,135,000 a year ago. Basic and diluted net loss per share attributable to common stock was $0.23 compared to $1.86 a year ago. For the six months, the company reported net loss of $6,559,000 compared to $3,534,000 a year ago. Loss from operations was $6,552,000 compared to $3,536,000 a year ago. Net loss attributable to common stock was $6,559,000 compared to $6,015,000 a year ago. Basic and diluted net loss per share attributable to common stock was $0.50 compared to $2.89 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXGN:US $2.03 USD +0.1099

OXGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXGN.
View Industry Companies
 

Industry Analysis

OXGN

Industry Average

Valuation OXGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 348.8x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXIGENE INC, please visit www.oxigene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.